Stocks and Investing
Stocks and Investing
Fri, May 12, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Maintained (VERA) at Strong Buy with Decreased Target to $10 on, May 12th, 2023
Ed Arce of HC Wainwright & Co., Maintained "Vera Therapeutics, Inc." (VERA) at Strong Buy with Decreased Target from $11 to $10 on, May 12th, 2023.
Ed has made no other calls on VERA in the last 4 months.
There is 1 other peer that has a rating on VERA. Out of the 1 peers that are also analyzing VERA, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $22 on, Wednesday, April 12th, 2023
Contributing Sources